R
Rosalin H. Arends
Researcher at University of Washington
Publications - 19
Citations - 1250
Rosalin H. Arends is an academic researcher from University of Washington. The author has contributed to research in topics: Medicine & Pharmacokinetics. The author has an hindex of 7, co-authored 7 publications receiving 757 citations. Previous affiliations of Rosalin H. Arends include Leiden University.
Papers
More filters
Journal ArticleDOI
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
Eric K. Rowinsky,Garry Schwartz,Jared A. Gollob,John A. Thompson,Nicholas J. Vogelzang,Robert A. Figlin,Ronald M. Bukowski,Naomi B. Haas,Pamela Lockbaum,Yu Ping Li,Rosalin H. Arends,Kenneth A. Foon,Gisela Schwab,Janice P. Dutcher +13 more
TL;DR: ABX-EGF was generally well tolerated and the objective response rate was low in previously treated patients with metastatic renal cell carcinoma, and its potential as a surrogate marker of clinical benefit requires further evaluation.
Journal ArticleDOI
Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil.
TL;DR: The four opioids studied demonstrate markedly different pharmacokinetic behavior, which correlates well with their pharmacodynamic behavior.
Journal ArticleDOI
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Myron J. Levin,Andrew Ustianowski,Stéphane De Wit,Odile Launay,Miles Avila,A. Templeton,Yuan Yuan,Seth Seegobin,A. Ellery,Dennis J. Levinson,Phil Ambery,Rosalin H. Arends,R Beavon,Kanika Dey,Pedro Garbes,Elizabeth J. Kelly,Gavin C. K. W. Koh,Karen A. Near,Kelly W Padilla,Konstantina Psachoulia,Audrey Sharbaugh,Katie Streicher,Menelas N. Pangalos,Mark T. Esser +23 more
TL;DR: A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns, and extended follow-up at a median of 6 months showed a relative risk reduction.
Journal ArticleDOI
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
Yueh Ming Loo,Patrick M. McTamney,Rosalin H. Arends,Michael E. Abram,Anastasia A. Aksyuk,Seme Diallo,Daniel J. Flores,Elizabeth J. Kelly,Kuishu Ren,Richard Roque,Kim Rosenthal,Katie Streicher,Kevin M. Tuffy,Nicholas J. Bond,Owen Cornwell,Jerome Bouquet,Li Cheng,J. Dunyak,Yue Huang,Anton I. Rosenbaum,Venkatesh Pilla Reddy,Hanne Andersen,Robert H. Carnahan,James E. Crowe,Ana I. Kuehne,Andrew S. Herbert,John M. Dye,Helen Bright,Nicole L. Kallewaard,Menelas N. Pangalos,Mark T. Esser +30 more
TL;DR: A combination of two mAbs that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2 are described and AZD7442 is projected to contribute to long-term human protection.
Journal ArticleDOI
Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
Louis M. Weiner,Arie S. Belldegrun,Jeffrey Crawford,Anthony W. Tolcher,Pamela Lockbaum,Rosalin H. Arends,Lynn Navale,Rafael G. Amado,Gisela Schwab,Robert A. Figlin +9 more
TL;DR: Panitumumab was well tolerated with comparable exposure and safety profiles for the weekly, every 2 weeks, and every 3 weeks administration schedules, most notably in patients with advanced colorectal cancer.